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plasticity. At synapses in the entorhinal cortex these receptors are tonically 
activated and provide a positive feedback modulation of the level of 
background excitation. NMDA receptor activation requires obligatory 
occupation of a co-agonist binding site, and in the present investigation we 
have examined whether this site on the presynaptic receptor is activated by 
endogenous glycine or D-serine. We used whole-cell patch clamp recordings 
of spontaneous AMPA receptor-mediated synaptic currents from rat entorhinal 
cortex neurones in vitro as a monitor of presynaptic glutamate release. 
Addition of exogenous glycine or D-serine had minimal effects on 
spontaneous release, suggesting that the co-agonist site was endogenously 
activated and likely to be saturated in our slices. This was supported by the 
observation that a co-agonist site antagonist reduced the frequency of 
spontaneous currents. Depletion of endogenous glycine by enzymatic 
breakdown with a bacterial glycine oxidase had little effect on glutamate 
release, whereas D-serine depletion with a yeast D-amino acid oxidase 
significantly reduced glutamate release, suggesting that D-serine is the 
endogenous agonist. Finally, the effects of D-serine depletion were mimicked 
by compromising astroglial cell function, and this was rescued by exogenous 
D-serine, indicating that astroglial cells are the provider of the D-serine that 
tonically activates the presynaptic NMDA receptor. We discuss the 
significance of these observations for the aetiology of epilepsy and possible 
targeting of the presynaptic NMDA receptor in anticonvulsant therapy. 
 
*Abstract
 1 
Astroglial D-serine is the endogenous co-agonist at the presynaptic 
NMDA receptor in rat entorhinal cortex 
 
 
 
Alex Lench1, Peter V. Massey1, Loredano Pollegioni2, Gavin L. Woodhall3 and 
Roland S. G. Jones1* 
 
 
1Department of Pharmacy and Pharmacology, University of Bath 
Bath BA2 7AY, United Kingdom 
 
 
2 Dipartimento di Biotecnologie e Scienze della Vita 
Università degli studi dell'Insubria, Varese, Italy. 
 
 
3School of Life and Health Sciences, Aston University 
Birmingham B4 7ET, United Kingdom 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Corresponding author: Professor Roland S.G. Jones, Department of 
Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath, BA2 
7AY, UK. 
Tel: +44-1225-383935 
Fax: +44-1225-386114 
E-mail: r.s.g.jones@bath.ac.uk 
 
  
*Manuscript
Click here to view linked References
 2 
 
Abstract 
Presynaptic NMDA receptors facilitate the release of glutamate at excitatory cortical 
synapses and are involved in regulation of synaptic dynamics and plasticity. At 
synapses in the entorhinal cortex these receptors are tonically activated and provide 
a positive feedback modulation of the level of background excitation. NMDA receptor 
activation requires obligatory occupation of a co-agonist binding site, and in the 
present investigation we have examined whether this site on the presynaptic 
receptor is activated by endogenous glycine or D-serine. We used whole-cell patch 
clamp recordings of spontaneous AMPA receptor-mediated synaptic currents from 
rat entorhinal cortex neurones in vitro as a monitor of presynaptic glutamate release. 
Addition of exogenous glycine or D-serine had minimal effects on spontaneous 
release, suggesting that the co-agonist site was endogenously activated and likely to 
be saturated in our slices. This was supported by the observation that a co-agonist 
site antagonist reduced the frequency of spontaneous currents. Depletion of 
endogenous glycine by enzymatic breakdown with a bacterial glycine oxidase had 
little effect on glutamate release, whereas D-serine depletion with a yeast D-amino 
acid oxidase significantly reduced glutamate release, suggesting that D-serine is the 
endogenous agonist. Finally, the effects of D-serine depletion were mimicked by 
compromising astroglial cell function, and this was rescued by exogenous D-serine, 
indicating that astroglial cells are the provider of the D-serine that tonically activates 
the presynaptic NMDA receptor. We discuss the significance of these observations 
for the aetiology of epilepsy and possible targeting of the presynaptic NMDA receptor 
in anticonvulsant therapy. 
 
Keywords: entorhinal cortex, presynaptic NMDA receptor, glycine, D-serine, 
glutamate release, astroglia 
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1. Introduction 
Transmitter release at central synapses and, hence, the strength of synaptic 
transmission is controlled on a moment-to-moment basis by activation of auto or 
heteroreceptors on presynaptic nerve terminals. At glutamate synapses, presynaptic 
NMDA receptors (preNMDArs) exert a tonic facilitatory effect on glutamate release 
and, thus, mediate an instantaneous form of synaptic plasticity. We first 
demonstrated this functional facilitatory effect at synapses in the rat medial 
entorhinal cortex (EC; Beretta and Jones, 1996a) and subsequently showed that it 
was mediated via Ca2+-entry via the receptor ionophore (probably di-heteromeric 
GluN1-GluN2B receptors) and could also contribute to activity-dependent facilitation, 
(Woodhall et al., 2001; Chamberlain et al., 2008). It is now apparent that preNMDArs 
are expressed at many sites throughout the CNS, and a widespread role of the 
receptors in control of transmitter release is likely (see Duguid and Smart, 2009). In 
particular, attention has increasingly focussed on a role in long-term synaptic 
plasticity of excitatory transmission (Humeau et al., 2003; Sjostrom et al., 2003; 
Samson and Pare, 2005; Corlew et al., 2007; Yang et al., 2008; Rodríguez-Moreno 
et al., 2010; Larsen et al., 2012). Our observation that preNMDAr are highly mobile 
in the presynaptic terminal membrane in the EC (Yang et al., 2008) could indicate an 
important role in metaplasticity as well. Enhanced expression or sensitivity of the 
preNMDAr may be involved in pathological plasticity associated with epilepsy 
(Steffens et al., 2005; Yang et al., 2006). 
NMDAr are modulated by a number of intrinsic regulatory mechanisms. In addition to 
partial relief from voltage dependent Mg2+-blockade, NMDAr activation requires 
binding of two agonists; the glutamate binding site is located on the GluN2 subunit 
and a co-agonist binding site resides on GluN1 subunits. Both glycine and D-serine 
are available as physiological ligands for the co-agonist site. Although glycine has 
generally been considered to be the endogenous co-agonist, more recent studies 
have indicated that D-serine is more likely to be the activator of the binding site at 
the postsynaptic NMDAr (postNMDAr), and that glycine is maintained at 
concentrations well below its affinity for the binding site by high-affinity transporters 
in the synaptic cleft (Fossat et al., 2011; Papouin et al., 2012). The source of the 
endogenous synaptic D-serine may well be adjacent astrocytes (Henneberger et al., 
 4 
2010; Fossat et al., 2011), although a neuronal origin has not been ruled out (e.g. 
(Wolosker et al., 1999; Kartvelishvily et al., 2006; Rosenberg et al., 2010)  
The EC plays a crucial role in declarative and spatial memory storage (e.g. 
Eichenbaum, 2001; Squire et al., 2004; Witter and Moser, 2006) and in limbic 
seizure generation and propagation in temporal lobe epilepsy (see Jones and 
Woodhall, 2005). To help understand the role of the preNMDAr in synaptic function 
in the EC we have investigated whether they are subject to regulation by 
endogenous glycine or D-serine, and whether this regulation may be necessary for 
tonic facilitation of spontaneous glutamate release. Li et al. (2007) previously 
showed that an antagonist at the NMDAr co-agonist site was able to reduce the 
spontaneous release of glutamate in visual cortex, an effect that was reversed by 
addition of glycine suggesting that endogenous activation of the co-agonist-binding 
site regulated tonic activation of preNMDArs in this area. In the present study we 
show that preNMDArs in the EC undergo a similar endogenous modification, that the 
endogenous agonist responsible for this is D-serine not glycine, and that the source 
of the D-serine is likely to be astroglial cells. 
2. Materials and Methods 
2.1 Ethics Statement 
All experiments were performed in accordance with the U.K. Animals (Scientific 
Procedures) Act 1986, European Communities Council Directive 1986 (86/609/EEC) 
and the University of Bath ethical review document, which requires that the number 
of animals used is kept to a minimum and every precaution was taken to reduce 
suffering and stress. At this institution, all research work involving use of animal 
tissue requires submission of a consideration of ethical implications by the principal 
investigator. This is reviewed by a second investigator, external to the research 
group, and by the Head of Department, and requires signatory approval from both 
before being reviewed by a Departmental Research Ethics Officer (DREO). The 
DREO discusses any issues raised with the investigator and submits a report to the 
University Ethics Committee detailing the ethical implications of all research within 
the Department. This ensures that the ethical implications of the research have been 
considered and that there is be a process in place for managing any ethical issues.  
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2.2 Slice preparation 
Brain slices were prepared (Jones and Heinemann, 1988) from juvenile Wistar rats 
(50-100g; P28-38). They were decapitated following cervical dislocation and the 
brain removed and submerged in oxygenated artificial cerebrospinal fluid (aCSF; see 
below for composition) at 4°C. Combined EC-hippocampal brain slices (350 µm 
thick) were cut at 4°C using a Campden Vibroslice and subsequently stored in 
oxygenated aCSF at room temperature. Slices were left to recover for 1 hour before 
being used for electrophysiological recording. The aCSF contained (in mM) NaCl 
(126), KCl (4), MgSO4 (1.25), NaH2PO4 (1.4), NaHCO3 (24), CaCl2 (2), D-glucose 
(10), ascorbic acid (0.57), sodium pyruvate (5) and creatinine monohydrate (5). To 
increase neuronal survival and viability, ketamine (4 µM), indomethacin (45 µM), 
aminoguanidine (25 µM), and Coomassie Brilliant Blue (250 nM) were included in the 
cutting solution, and the antioxidants, n-acetyl-L-cysteine (2 µM) and uric acid (100 
µM), added to both cutting and storage solutions. We have established that the use 
of the additives facilitates production robust and viable slices, but does not affect on 
the pharmacology of glutamate transmission.  
2.3 Whole-cell patch clamp recordings.  
After a period of recovery at room temperature, slices were transferred to a chamber 
on an Olympus BX50WI microscope perfused (2 ml/min) with oxygenated aCSF at 
31-32°C, where they were allowed to equilibrate before recording commenced. 
Individual neurones were visualized using DIC optics and an infrared video camera. 
Whole cell patch clamp recordings were made with an Axopatch 200A amplifier 
using pipettes pulled from borosilicate glass on a Flaming-Brown microelectrode 
puller. AMPA receptor mediated spontaneous excitatory post synaptic currents 
(sEPSCs) were recorded using a Cs-gluconate based solution intracellular solution 
containing (in mM) D-gluconate (100), HEPES (40), QX-314 (1), EGTA (0.6), NaCl 
(2), Mg-gluconate (5), TEA-Cl (5), phosphocreatinine (10), ATP-Na (4), GTP-Na (0.3) 
and MK801 (5mM). The solution was adjusted to 275-290 mOsm by dilution and pH 
7.3 with CsOH. MK-801 was included in the patch pipettes to allow us to record 
AMPA-receptor mediated responses in isolation and to monitor activity at 
preNMDArs uncontaminated by postsynaptic receptor effects. We developed and 
validated this approach (Berretta and Jones, 1996b; Woodhall et al., 2001; Yang et 
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al., 2006, 2008), and others have used it successfully to block postNMDArs in 
recorded neurones (Sjostrom et al., 2003; Samson and Pare, 2005; Bender et al., 
2006; Jourdain et al., 2007; Li and Han, 2007; Brasier and Feldman, 2008). 
EPSCs were recorded at a holding potential -60mV. Signals were filtered at 2 kHz, 
digitised at 50kHz, and stored using AxoScope software. Series resistance 
compensation was not employed, but access resistance was monitored at 5-minute 
intervals throughout recording and cells where it varied by greater than 15% were 
excluded from analysis. Input resistances for the neurones recorded in these studies 
were of the order 500-70 MΩ. Data recording commenced 10-15 minutes after 
gaining whole cell access and then continued for at least 15 minutes during control 
and each drug treatment condition. Miniature EPSCs (mEPSCs) were isolated using 
tetrodotoxin (TTX; 1µM). EPSCs were analysed offline over a stable 5-minute period 
of recording where spontaneous events were detected using a threshold-crossing 
algorithm with Minianalysis software (Synaptosoft, Decatur).  
The average frequency, calculated across a 5-minute epoch, was compared before 
and after drug application. To compare amplitudes of spontaneous currents we 
determined median values for each neurone in the same 5-minute period as these 
better reflect the population distributions (normal distribution with a slight skew 
towards larger amplitude events) than arithmetical means. Median values were then 
averaged in the neuronal populations for comparative illustrative purposes. We have 
used this approach in a previous study to characterize IPSCs in the same neuronal 
population (Woodhall et al., 2005). Event kinetics were compared via arithmetical 
means. Statistical comparison of drug effects on mean frequency and kinetics and 
mean median amplitudes within cells employed a two-tailed paired t-test. In 
experiments involving matched slices with and without prior enzyme treatment, 
comparison between neurones was assessed using a two-way ANOVA. In some 
experiments involving pooled data, we additionally compared cumulative probability 
distributions of interevent intervals using a Kolmogorov-Smirnov test. 
2.4 Enzymatic depletion of endogenous D-serine and glycine 
To determine whether glycine or D-serine is the endogenous activator of the co-
agonist site we depleted one or other of the amino acids from the slices by 
preincubation with selective enzyme scavengers. A yeast D-amino acid oxidase 
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(DAAO), was used to degrade D-serine, whereas a bacterial glycine oxidase (GO) 
was used to target glycine. Recombinant Rhodotorula gracilis DAAO (RgDAAO) and 
Bacillus subtilis glycine oxidase GO (BsGO) were overexpressed in Escherichia coli 
cells and then purified as described previously (Fantinato et al., 2001; Job et al., 
2002). In experiments where they were employed, slices were incubated with 
enzymes at room temperature in the recording chamber for at least 45 minutes prior 
to recording, and then continuously during recording period at 32oC. Matched slices 
in normal buffer were treated in the same way and alternated with the enzyme 
treated slices. For each experiment a single neurone was recorded from an enzyme 
treated slice, and a second recording was made in an untreated slice from the same 
animal on that day, so that neurones were matched in that animal. The order of 
recording (treated or untreated) was varied from animal to animal. 
2.5 Source of D-serine in EC 
 Previous studies have suggested that a principal source of D-serine in slices is 
release from astroglial cells (Kartvelishvily et al., 2006; Miya et al., 2008; Rosenberg 
et al., 2010). The metabolic status of astroglial cells is compromised by sodium 
fluoroactetate (NFAc). Accordingly we have determined the effect of NFAc on 
spontaneous release of glutamate in EC. In experiments where this was tested, 
slices were incubated with NFAc in the recording chamber for at least 35 minutes 
prior to recording, and also continuously during the recording period. Matched slices 
in normal buffer were treated in the same way and alternated with the NFAc treated 
slices. 
2.6 Materials 
Salts used in preparation of aCSF were purchased from Merck/BDH or Fisher 
Scientific (UK). Indomethacin, aminoguanidine, n-acetyl-L-cysteine, uric acid, 
Coomassie Brilliant Blue, NFAc and agents used in the preparation of the patch 
pipette solution, apart from QX-314 (Tocris, UK), were purchased from Sigma (UK). 
Ketamine was supplied by Fort Dodge Animal Health Ltd (Southampton, UK). Drugs 
were generally stored as frozen, concentrated stock solutions in distilled water and 
applied by dilution in the aCSF perfusion immediately before use. The following 
drugs were supplied by Tocris UK or Ascent Scientific UK: 2-AP5 (D-2-amino-5-
phosphonopentanoic acid), DCKA (5,7-dichlorokynurenic acid), CPPG ((RS)-α-
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Cyclopropyl-4-phosphonophenylglycine), MCPG ((RS)-α-Methyl-4-carboxyphenyl-
glycine), MK801, glycine, suramin hexasodium salt, CGS15943, D-serine and TTX. 
UBP 141 was a kind gift from Professor David Jane, University of Bristol. 
3. Results 
The experiments were performed on neurones in layer V of the medial EC. Although 
not specifically identified by dye injection, all the selected neurones had identifiable 
pyramidal cell morphology when viewed with DIC. We stress that all recordings were 
of AMPA-receptor mediated s/mEPSCs with postNMDArs blocked in the recorded 
neurone by intracellular dialysis with MK801. 
3.1 Effects of D-serine and glycine 
The effects of exogenously applied glycine (100 µM) were tested on 4 neurones and 
the effects are summarised in Fig. 1A. The mean frequency of mEPSCs in these 
neurones was 0.75±0.13 Hz in control conditions. This was similar (0.73±0.12 Hz; -
4%) in the presence of glycine (Fig. 1A) and there was no significant difference when 
assessed with a paired t-test. We also compared cumulative probability distributions 
of interevent interval, and KS analysis showed no significant shift in distribution in the 
presence of glycine reflecting the lack of change in frequency. mEPSCs had a mean 
median amplitude of 6.4±0.2 pA in control and this was not significantly altered 
during perfusion with glycine (6.0±0.2 pA). Additionally, neither sEPSC rise (4.7±0.8 
ms v 5.3±0.3 ms) nor decay time (6.3±1.2 ms v 6.3±0.3 ms) changed during 
perfusion with the amino acid.  
Similar studies were performed with D-serine (100 µM; n=4; Fig. 1B). As with 
glycine, there was no significant change in mean frequency of mEPSCs (0.51±0.06 
Hz v 0.56±0.15 Hz; +11%) during perfusion with the amino acid when assessed with 
a paired t-test. However, there was a small but significant shift to the left of the 
cumulative probability distribution of events when the data were analysed as 
interevent interval distributions and compared with a Kolmogorov-Smirnov test 
(P<0.05). This change was not pronounced but was the only significant change 
detected. Mean median amplitude (6.7±0.1 pA v 6.5±0.3 pA), mean rise (4.3±0.3 ms 
v 4.5±0.3 ms) and mean decay time (5.5±0.3 ms v 6.5±0.3ms) were unaltered by D-
serine. 
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3.2 The preNMDAR co-agonist binding site is tonically activated  
The failure of either glycine or D-serine to substantially increase the release of 
glutamate may suggest that the co-agonist binding site of the preNMDAr is tonically 
activated at a level close to saturation in the EC. If this is the case then blocking the 
site should result in a decrease in release. To investigate this we examined the effect 
of DCKA, a co-agonist binding site antagonist. Although postNMDArs were blocked 
in the recorded neurones by intracellular MK801, these experiments (n=4) were 
again conducted on mEPSCs to avoid any complicating effects of network activity via 
non-recorded neurones in which the postNMDArs were not blocked. The results are 
shown in Fig. 2A. DCKA elicited a significant decrease in mEPSC frequency to 
around 50% of the control level. This effect was not accompanied by any change in 
mean amplitude (8.37±0.5 v 7.8±0.4 pA), rise time (4.8±0.3 v 4.8±0.4 ms) or decay 
time (5.8±0.5 v 6.0±0.7 ms), and this lack of effect on mEPSCs is shown by the 
averaged events and the lack of change in amplitude distribution in Fig 2A. Overall, 
these effects indicate that DCKA acts presynaptically to reduce the probability of 
glutamate release. 
To confirm that the effect of DCKA was likely to be mediated via an action at 
preNMDAr we examined its effect in the presence of the competitive NMDAr 
antagonist, 2-AP5 (n=5; Fig. 2B). In accordance with our previous findings (Berretta 
and Jones, 1996a; Woodhall et al., 2001), 2-AP5 induced a significant decrease in 
mEPSC frequency (0.47±0.04 v 0.29±0.05 Hz) without change in amplitude (8.0±0.8 
v 7.6±0.7 pA). Subsequent perfusion with DCKA in the presence of 2-AP5 now failed 
to induce any further change in frequency. Thus, the occlusion of the effects of 
DCKA by the competitive receptor antagonist suggests that it is acting at preNMDArs 
and blocking the tonic facilitation of release enabled by binding of endogenous 
glutamate and a co-agonist. 
3.3 Glycine does not endogenously activate the co-agonist binding site 
Having determined that the co-agonist binding site of the preNMDAr was tonically 
and endogenously activated in our slices we then attempted to identify the 
endogenous ligand responsible. The small, but significant decrease in interevent 
interval induced by D-serine could suggest that the D-serine is the preferred ligand 
for the co-agonist binding site. To look at this further we selectively depleted the 
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candidate ligands via enzymatic breakdown. This approach has been successfully 
used to look at endogenous ligands for the postNMDAr (Fossat et al., 2011; Papouin 
et al., 2012). In the first set of experiments we examined the effect of degrading 
endogenous glycine with BsGO. We compared the characteristics of mEPSCs in 6 
neurones in untreated brain slices to matched neurones in brain slices incubated 
with BsGO for 45 minutes. 
Fig. 3 illustrates the results of these experiments. The frequency of mEPSCs 
(0.41±0.13 Hz ) in slices preincubated with BsGO (n=6) was not significantly different 
to that in matched slices without enzyme present (0.33±0.04 Hz). Likewise, the mean 
amplitudes (7.7±0.4 v 7.9±0.9 pA), amplitude distribution (Fig. 3), and kinetics in 
treated and untreated slices (rise time 4.4±0.4 v 4.3±0.4 ms; decay time 7.1±0.8 v 
7.2±0.7 ms) were not significantly affected by the enzyme treatment. These data 
clearly suggest that endogenous glycine is unlikely to be tonically activating the 
binding site on the preNMDAr. To confirm that the site was still being activated we 
determined the effect of DCKA in both naïve and enzyme treated slices. In both 
cases, the co-agonist site antagonist, as described above, reduced the frequency of 
mEPSCs (Fig. 3) without altering either amplitude distribution (Fig. 3) or kinetics 
(data not shown). 
3.4 D-serine endogenously activates the co-agonist site 
We next examined the effect of removal of endogenous D-serine from our slices by 
incubation with the yeast enzyme, RgDAAO, which specifically degrades D-serine 
(Fig. 4). The mean frequency of mEPSCs in 6 neurones in untreated slices was 
0.65±0.13 Hz. However, in 6 neurones in slices incubated with RgDAAO, mEPSC 
frequency was lowered to 0.38±0.03 Hz. This substantial decline in frequency was 
not accompanied by differences in mean event amplitude (7.8±0.5 pA v 7.3±0.3 pA), 
kinetics (rise time 4.7±0.3 v 5.1±0.3 ms; decay time 6.0±0.4 v 5.9±0.7 ms) or 
amplitude distribution (Fig. 4). As in the glycine experiments, we also studied the 
effects of DCKA. In naïve slices DCKA reduced the frequency of mEPSCs without 
change in amplitude or kinetics, as described above. However, pre-treatment with 
RgDAAO now occluded the effects of DCKA, and the co-agonist site antagonist 
caused no further reduction in frequency and no change in amplitude distribution 
(Fig.4). These results indicate that D-serine is likely to be the endogenous co-agonist 
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at the preNMDAr, and that glycine, at least in the conditions pertaining in our slices, 
may play little role in this regard. 
3.5 Astrocytes may be the source of endogenous D-serine. 
Previous studies have shown that D-serine is the likely to be the endogenous co-
agonist at subsynaptic postNMDAr in cortex (Fossat et al., 2011; Papouin et al., 
2012) and that astroglia may be the source of the D-serine. We have looked at the 
possibility that astroglial D-serine may be the endogenous activator of preNMDArs in 
the EC. To this end we compared mEPSCs in neurones with and without 
preincubation with the glia-specific metabolic inhibitor, NFAc (Hassel et al., 1997; 
Hulsmann et al., 2003; Andersson et al., 2007; Okada-Ogawa et al., 2009). The 
results are summarized in Fig. 5A. In 6 neurones recorded in naïve slices, mEPSC 
frequency was 0.66 ± 0.13 Hz and mean amplitude was 7.0±0.7 pA. In matched 
recordings from slices pre-incubated with NFAc (n=6), mEPSC frequency was much 
lower at 0.35±0.03 Hz, but there was no change in mean amplitude (7.1±0.5 pA). 
The amplitude distribution of mEPSCs was also unaltered and there were no 
differences in either rise or decay times in the two groups (not shown). We also 
tested the effects of the co-agonist site antagonist in the presence or absence of 
NFAc (Fig. 5A). In the untreated slices DCKA reduced the frequency of mEPSCs, as 
noted above. However, when tested in NFAc-treated slices, DCKA had little further 
effect on mEPSC frequency. Comparison of the effect of DCKA in the two sets of 
slices showed a trend towards a bigger reduction in frequency when combined with 
NFAc, but this was not significant. 
Thus, compromising astroglial function induced a similar reduction in spontaneous 
release of glutamate to that seen with a co-agonist site antagonist, or enzymatic 
degradation of D-serine with RgDAAO, suggesting that astroglial release provides 
the D-serine required for tonic activation of the preNMDAr. However, the effect of 
incubation with NFAc was somewhat less than that of RgDAAO (cf. Fig. 4) and we 
cannot exclude the possible influence of neuronal D-serine at the preNMDAR.  
We next examined the ability of exogenous D-serine to rescue the reduction in 
mEPSC frequency induced by pre-incubation with NFAc in four slices. In 5 neurones 
the mean frequency of mEPSCs was again lower than that seen in naïve slices and 
a significant recovery was seen upon addition of D-serine (100µM; Fig. 5B), 
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suggesting that it was indeed the loss of an endogenous d-serine supply from 
astroglial that resulted in a decline of tonic facilitation.  
We also determined whether a loss of endogenous D-serine would also reduce the 
ability of direct activation of preNMDAr to facilitate glutamate release. To this end we 
compared the ability of NMDA to increase mEPSC frequency in the presence or 
absence of NFAc. In control neurones (n=5), application of NMDA (100 µM) elicited 
a increase in frequency of mEPSCs of 131% (from 0.56±0.17 Hz to 1.03±0.25 Hz) 
with no change in amplitude (7.4±0.5 pA v 7.4±0.3 pA). In 5 matched neurones 
treated with NFAc, the increase in frequency seen with NMDA was only 58% 
(0.32±0.08Hz v 0.49±0.12 Hz), again without change in amplitude (7.5±0.5 pA v 
7.2±0.6 pA). 
3.6 Effects of UBP 141, purinergic receptor blockade and mGluR antagonists  
Thus, the most parsimonious explanation of our data is that D-serine released from 
astrocytes is likely to be the co-agonist at the preNMDAr on nerve terminals. 
However, there are a number of other possible, and more complex, interpretations. 
and we have attempted to rule some of these out with pharmacological approaches. 
Astrocytes themselves express NMDAr, and it has been suggested that these are 
involved in neurone-to-glia signalling and vice versa (Lalo et al., 2006; Palygin et al., 
2011). If these NMDAr responded to ambient glutamate level, this could result in 
tonic release of astrocytic glutamate or other gliotransmitters (e.g. purines). This 
could complicate our interpretations, since treatments aimed to modify the co-agonist 
site could target the astrocyte NMDAr rather than the terminal receptors. We have 
shown that the preNMDAr in EC is likely to be principally, if not exclusively, a GluN1- 
GluN2B heteromer (Woodhall et al, 2001; Yang et al., 2006; Chamberlain et al., 
2008). Recent studies have suggested that NMDAr on cortical astrocytes may be 
largely GluN2C/D-N3containing (Palygin et al., 2011). We tested the effects of the 
relatively specific GluN2C/D antagonist, UBP 141 (2.5 µM; Morley et al., 2005) alone 
and in combination with DCKA. The mean frequency of mEPSCs in control 
conditions (n=4) was 0.43±0.09 Hz and this was unaltered by UBP 141 (0.45±0.08 
Hz), but subsequently reduced by DCKA (0.21±0.02 Hz) in the continued presence 
of the antagonist. This argues against the reduction in tonic glutamate release 
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induced by the co-agonist blocker occurring via an interaction with NMDAr on 
astrocytes. 
Notwithstanding the failure of UBP 141 to alter the release of glutamate or the effects 
of DCKA we have considered other further scenarios dependent upon NMDAr 
activation of astrocytes by ambient glutamate. One possibility could involve a 
complex cascade mediated by purinergic transmitters. NMDAr activation can release 
ATP from astrocytes, and also lead, directly via release or indirectly via metabolism 
of ATP, to accumulation of extracellular adenosine (e.g. see Queiroz et al., 1997; 
Pascual et al., 2005; Wall and Dale, 2013). Subsequent activation of purinergic 
receptors on neurones or glia could then potentially amplify tonic release of 
glutamate. Thus, the decrease in glutamate release seen with DCKA or scavenging 
of D-serine could result not from compromising preNMDAr but rather those on the 
glial cells. We felt that this was unlikely on the basis of the UBP 141 experiments, but 
also because we have previously shown that both ATP and adenosine reduce, rather 
than enhance glutamate release in the EC (Saunders, J. and Jones R.S.G., 
unpublished). However, since the potential mechanism would depend on tonic 
activation of glutamate release by the astrocytic derived purines, we examined its 
viability by testing DCKA in the presence of broad spectrum purinergic receptor 
antagonists; suramin, which non-specifically targets P2 receptors, and CGS15943, 
which blocks A1, A2A, A2B and A3 adenosine receptors. Neither frequency (0.50±0.07 
v 0.45±0.04 Hz) nor amplitude (9.6±1.9 v 9.3±1.8 pA) of mEPSCs was altered by 
suramin (100µM, n=4). Subsequent perfusion with DCKA, in the continued presence 
of suramin, elicited a similar reduction in frequency (to 0.24±0.02Hz) to that seen 
with the co-agonist blocker alone (Section 3.2), again without change in amplitude 
(8.2±1.4 pA). Likewise, studies with CGS15943 (1µM, n=4) showed no change in 
frequency with the adenosine antagonist alone (0.30±0.22 v 0.29±0.07 Hz), but a 
significant decrease with subsequent addition of DCKA (0.19±0.04 Hz). 
One further alternative mechanism could involve activation of metabotropic 
glutamate receptors (mGluR). Glutamate, released from astrocytes in response to 
NMDAr activation, has been shown to further tonically increase neuronal glutamate 
release via mGluRs (e.g. see Fiacco and McCarthy, 2004; Clasadonte and Haydon, 
2012). If such a situation was operative at EC synapses, then negatively modifying 
the co-agonist activation of astrocytic NMDAr could indirectly manifest itself as a 
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reduced frequency of mEPSCs. We have shown previously that agonists at group III 
(Evans et al, 2000), group II (Morgan, N. et al, unpublished) and group I mGluR 
(Yang, J. et al, unpublished) agonists can all (under some circumstances) facilitate 
spontaneous release of glutamate in layer V of the EC, so such a scenario is 
possible. However, again for it to be viable the mGluRs in question would have to be 
tonically activated. However, we have also shown that the group III receptor 
antagonist, CPPG does not affect mEPSC frequency (Evans et al., 2000). We now 
report here that mEPSC frequency is unaltered (0.66±0.10 v 0.71±0.09 Hz) by the 
group II mGluR antagonist, LY341495 (20 nM, n=7) or by the group I/II antagonist, 
MCPG (300 µM; 0.81±0.11 v 0.75±1.0 Hz; n=5). Neither the group III or the group I/II 
antagonist altered mEPSC amplitude (not shown) although there was a slight but 
significant increase in amplitude with LY341495 (12.3±0.2 pA v 14.1±0.2 pA; P < 
0.05). Overall these results suggest that mGluR activation following astroglial 
glutamate release is unlikely to be a complicating factor in the current study. 
4. Discussion 
The obligatory binding of a co-agonist amino acid to a binding site on the NMDAr for 
its activation was demonstrated 25 years ago (Johnson and Ascher, 1987; Forsythe 
et al., 1988; Kleckner and Dingledine, 1988). Enhancement of NMDAr-mediated 
responses by glycine initially suggested that this amino acid was the endogenous co-
agonist (Johnson and Ascher, 1987; Berger et al., 1998; Bergeron et al., 1998; 
Forsythe et al., 1988; Kleckner and Dingledine, 1988) and, accordingly, the 
nomenclature ―glycine-binding site‖ received common usage. However, increasing 
evidence has pointed to D-serine as an alternative endogenous co-agonist (Mothet 
et al., 2000; Yang et al., 2003; Basu et al., 2009; Henneberger et al., 2010; Fossat et 
al., 2010), although a recent study (Papouin et al., 2012) suggests that synaptic 
(GluN2A-containing) and extrasynaptic (GluN2B-containing) NMDAr may be 
differentially gated by D-serine and glycine, respectively (see below). All these 
studies relate to postNMDArs, and co-agonist gating of preNMDArs has received 
much less attention. 
PreNMDArs facilitate the release of glutamate at cortical synapses (Berretta and 
Jones, 1996a; Woodhall et al., 2001; Sjostrom et al., 2003; Li and Han, 2007 Li et 
al., 2008). This effect is tonically expressed and dependent on ambient glutamate, 
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but, of necessity, it will also require tonic activation of the obligatory co-agonist 
binding site. We have studied the basis of a co-agonist regulation of glutamate 
release at synapses in layer V of the EC. Neither glycine nor D-serine had any 
substantial effect on frequency, amplitude or kinetics of AMPA receptor-mediated 
sEPSCs, although cumulative probability analysis of inter-event interval did indicate 
a slight increase in frequency with D-serine but not glycine. This could support a 
preference for D-serine as the endogenous co-agonist, but overall the data suggest 
that co-agonist binding site is saturated, or close to it, under baseline conditions. The 
endogenous occupation of the preNMDAr co-agonist binding site was confirmed by 
application of a competitive antagonist, DCKA, which clearly decreased the 
frequency of EPSCs. The occlusion of this effect by prior application of 2-AP5 
indicated that DCKA was acting at the co-agonist site on the preNMDAr. Thus, at 
these synapses, the levels of ambient glutamate and its co-agonist at the preNMDAr 
can modulate control and maintenance of spontaneous excitation. Li and Han (2007) 
conducted similar studies in rat visual cortex. They also found little effect of 
exogenous glycine or D-serine, but noted a decrease in probability of release with a 
co-agonist binding site blocker, although all their recordings were done in Mg-free 
conditions so may not be directly comparable. 
Using specific scavenging enzymes for glycine and D-serine, we have now shown 
that the endogenous co-agonist occupying the preNMDAr in the EC is almost 
certainly D-serine rather than glycine. Previous studies have strongly suggested that 
D-serine acts as the endogenous co-agonist at NMDArs at many postsynaptic sites 
(Mothet et al., 2000; Yang et al., 2003; Basu et al., 2009; Henneberger et al., 2010; 
Fossat et al., 2010), and that glycine uptake transporters are powerful enough to 
maintain extracellular glycine below its affinity for the NMDAr co-agonist site (Fossat 
et al., 2011; Papouin et al., 2012). Interestingly, Papouin et al., (2012) have recently 
suggested that postNMDArs, located subsynaptically in CA1, are preferentially gated 
by D-serine, whilst those at extrasynaptic sites preferentially bind glycine. Further, 
they suggest that this is related to the fact that subsynaptic receptors are principally 
GluN2A heterodimers which have a higher affinity for D-serine (Priestly et al., 1995; 
Madry et al., 2007), whereas extrasynaptically they are GluN2B-containing, which 
have a higher affinity for glycine (Priestly et al., 1995; Wafford et al., 2005; Madry et 
al., 2007). We have shown (Woodhall et al., 2001; Yang et al., 2006; Chamberlain et 
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al., 2008) that the preNMDAr in the EC has a diheterodimeric GluN1-GluN2B subunit 
composition (likewise in the visual cortex; Li et al., 2008). It might be expected 
therefore that they would preferentially bind and be gated by glycine rather than D-
serine, but this was clearly not the case. Thus, the preNMDARs may represent a 
pharmacologically distinct population of NMDAr that are bound by endogenous D-
serine whilst lacking GluN2A subunits.  
Glutamate released from astrocytes can activate neuronal NMDArs (Parri et al., 
2001) and it has been shown that this is associated with an increase in sEPSCs, 
possibly via a presynaptic mechanism (Araque et al., 1998). Jourdain et al., (2007) 
confirmed that astrocytic derived glutamate could boost synaptic strength by 
activating neuronal preNMDArs. We asked what was the source of D-serine that 
tonically co-activates the preNMDAr? Serine racemase (the enzyme that reversibly 
converts L- to D-serine) and D-serine have been largely localized to astrocytes in the 
brain, although there is evidence that cortical neurones may also be asource of the 
endogenous amino acid (Wolosker et al., 1999; Kartvelishvily et al., 2006; Martineau 
et al., 2006; Williams et al., 2006; Miya et al., 2008; Rosenberg et al., 2010), so there 
is still debate over whether postNMDArs are activated by D-serine release from 
astrocytes or neurones (e.g. see Rosenberg et al., 2010; Fossat et al., 2011). We 
found that inhibiting metabolic activity in astrocytes with NFAc, had the same effect 
on glutamate release in the EC as scavenging D-serine with RgDAAO, or blocking 
the co-agonist binding site with DCKA. This strongly suggests that the preNMDAr is 
gated by astrocytic D-serine in the EC, rather than neuronal D-serine. However, a 
weak, (although insignificant), reduction of glutamate release by DCKA in the 
presence of NFAc, means we cannot entirely rule out a neuronal contribution. 
Interestingly, a recent study has shown that D-Serine release is increased in rat 
hippocampus by Isoleucine via exchange at the asc-1 (alanine–serine–cysteine 
transporter-1) and this results in enhanced NMDAr-dependent LTP (Rosenberg et 
al., 2013). We have previously shown that spontaneous glutamate release in layer V 
of the EC is unaltered by L-Isoleucine (Cunningham et al., 2004), which is essentially 
equieffective with D-Isoleucine as a substrate for asc-1 (Fukasawa et al., 2000: 
Helboe et al., 2003). As asc-1 is not expressed in astrocytes (Helboe et al., 2003; 
Rosenberg et al., 2013), this could taken as support for a glial, rather than neuronal 
source of endogenous D-Serine in the EC. 
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 However, overall the picture emerges that activation of preNMDAr and the resultant 
increase in synaptic activation, may well depend on interaction between glutamate, 
of neuronal origin, and D-serine from astrocytes at tripartite cortical synapses. We 
believe that this is the most parsimonious explanation of our results. However, since 
astrocytes themselves express NMDAr, activation of which can lead to release of 
glutamate and purinergic transmitters, other more complex scenarios are possible, 
which could reflect co-agonist regulation of glial, rather than terminal NMDAr. We 
have used pharmacological approaches to look at these possibilities and believe that 
we have largely ruled out a contribution of glial NMDAr dependent activation of ATP, 
adenosine or mGluR as complicating factors in our studies. Thus, whilst we cannot 
be 100%, we are, nevertheless, confident that preNMDAr on terminals at layer V 
synapses are co-activated by neuronal glutamate and astrocytic D-Serine. 
What are the implications of the tonic co-agonist regulation of preNMDAr for synaptic 
function in the EC? One interesting possibility is in control of presynaptic receptor 
trafficking. We have previously shown (Yang et al., 2008) that preNMDArs can 
diffuse laterally within the presynaptic membrane moving between sites proximal and 
distal to the active release sites, providing a basis for an activity-dependent tonic 
regulation of glutamate release and hence synaptic strength. Recent work has 
suggested that GluN2B-containing postNMDAr have their lateral mobility restricted 
by D-serine (Papouin et al., 2012). We do not know yet whether the co-agonist 
binding of D-serine similarly slows diffusion of the preNMDAr, but such an effect, 
mediated by astroglial activity, could provide a basis for an activity-dependent 
metaplasticity of transmission at excitatory synapses in the EC. 
Interestingly, reactive astrocytosis is a feature of human temporal lobe epilepsy and 
animal models of the chronic condition (Borges et al., 2003; 2006; Cohen-Gadol et 
al., 2004; Eid et al., 2008; Shapiro et al., 2008; Wetherington et al., 2008). A 
decrease in glutamine synthase activity in association with this has been suggested 
to elevate synaptic levels of glutamate (see Clasadonte and Haydon, 2012). 
Furthermore, increased levels of D-serine and serine racemase levels have been 
observed in pilocarpine induced epilepsy (Ryu et al., 2010). We have previously 
shown an enhanced tonic facilitation of glutamate release of preNMDAr in a similar 
model of chronic epilepsy (Yang et al., 2006), and human temporal lobe epilepsy 
may be associated with an increased density of preNMDAr at cortical synapses 
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(Steffens et al., 2005). Thus, in temporal lobe epilepsy, we may have a situation 
where increased effectiveness of preNMDAr per se, may be exacerbated by an 
elevation of synaptic availability of both co-agonists, as a result of reactive gliosis, 
leading to a pathological rise in cortical network excitability and synchrony.  
Pharmacologically targeting the astroglial-preNMDAr synaptic amplifier may, 
therefore, provide a useful therapeutic approach to epilepsy. Use of NMDAr co-
agonist binding site blockers has already received consideration (Chiamulera et al., 
1990; Singh et al., 1990; Peterson, 1991; Peeters and Vanderheyden, 1992; Wu et 
al., 2002). Interestingly, we have previously demonstrated that felbamate can reduce 
glutamate release in the EC via an action at preNMDArs (Yang et al., 2007), and the 
drug may act, at least in part, by blocking the glycine/D-serine co-agonist binding site 
(White et al., 1995; Kuo et al., 2004; Chang and Kuo, 2007). The co-agonist binding 
site partial agonist, cycloserine, has anticonvulsant activity (Chung et al., 1984; 
Baran et al., 1994; De Sarro et al., 2000; see also Ghasemi and Schachter, 2011), 
and acts as an antagonist only when a high degree of agonist occupancy of the site 
is present (Henderson et al, 1990). We have shown here that the preNMDAr co-
agonist binding site in the EC is likely to be endogenously saturated so this approach 
may be useful in achieving a degree of selectivity for blocking the receptor. The pro-
drug, 4-chlorokynurenine, which is largely inactive but undergoes astrocytic 
conversion to the co-agonist binding site blocker, 7-chlorokynuerenic acid (Zhang et 
al., 2005), could also be an alternative approach to epilepsy therapy. Finally, 
inhibition of serine racemase (Panizzutti et al., 2001) or enzymatic metabolism of D-
serine (Sacchi et al., 2012) could also provide promising strategies for the 
development of treatments for epilepsy.  
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Figure Legends 
Fig. 1: Effect of D-serine and glycine on sEPSCs in EC neurones. A. The traces 
show averaged mEPScs in the presence and absence of glycine in a single layer V 
neurone in the EC. The addition of glycine had little effect on the excitatory events. 
Pooled data from 4 neurones in the bar graphs show that neither mean frequency 
nor amplitude nor was significantly altered. B. Studies with D-serine produced very 
similar results. A slight increase in mean frequency was not significant.  
Fig. 2: A co-agonist site antagonist reduces spontaneous glutamate release. A.  
Application of the co-agonist binding site antagonist, DCKA (n=5), produced a robust 
decrease in mEPSC frequency, but was without effect on event amplitude. The 
averaged traces from one neurone show no change in event amplitude or kinetics, 
and the lack of change in amplitude is also reflected in the frequency distributions of 
pooled data. B. The competitive glutamate binding site antagonist, 2-AP5 induced a 
similar decrease in mEPSC frequency to that seen with DCKA, and also occluded 
the effect of the latter. In this and subsequent figures, * = P<0.05 and ‗ns‘ denotes 
not significant. 
Fig. 3: Depletion of endogenous glycine does not affect spontaneous glutamate 
release. Comparison of mEPSC frequencies with and without pre-incubation with 
BsGO showed no significant difference between matched control slices and slices 
incubated with the enzyme (n=6 in each case). In the naïve slices, as noted in Fig. 2, 
DCKA elicited a significant reduction in mEPSC frequency, and this effect was very 
similar in the enzyme-treated slices. There were no differences in event amplitudes 
in any of the experimental situations and this is illustrated by the overlapping 
frequency distributions  
Fig. 4: Depletion of endogenous D-serine reduces spontaneous glutamate release.  
Pre-incubation of slices with the D-amino acid oxidase, RgDAAO to degrade 
endogenous D-serine resulted in a significant decrease in mEPSC frequency in 
comparison to matched untreated slices  (n=6 in each case). This reduction was 
similar to that seen with the co-agonist binding site antagonist, DCKA, and the effect 
of the latter was occluded by pre-incubation with the enzyme. Despite the change in 
frequency event amplitudes were unaltered, exemplified by the overlapping 
frequency distributions of amplitudes from pooled data. 
 28 
Fig. 5: Compromising astroglial function reduces spontaneous glutamate release. A. 
In slices pre-incubated with NFAc (n=6), mEPSC frequency was substantially 
reduced compared to neurones in matched control slices (n=6), and this effect was 
similar to that seen with DCKA and RgDAAO (Figs. 2 and 4). However, the effect of 
DCKA was occluded by pre-incubation with NFAc. Amplitude distributions were 
unaffected by any of the experimental treatments. B. The reduction in mEPSC 
frequency seen with NFAc was partially rescued by application of D-serine. Thus, in 
contrast to the situation in untreated slices (Fig. 1), perfusion with D-serine increased 
the frequency of mEPSCs in NFAc-treated slices with no effect on amplitude 
distribution. 
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